Atlas Bio Funding Round

10/27/2026

Venture Equity

$10,000,000

Seed

Atlas Bio will use the funding to scale scientific and commercial teams, deepen platform validation, and onboard further enterprise clients through 2026.

Private & Independent

Biopharmaceutical

Sandgrubenstrasse 44
Basel, 4058
Switzerland

Undisclosed

Not Recorded

Atlas runs in silico clinical trials in immunology using its foundation AI model of human biology to predict and compare patient responses across treatments and indications, helping biopharma teams decide what to advance, acquire or expand. We start from a treatment's mechanism of action and apply it to patient readouts from Atlas's proprietary datasets. Our AI model predicts how these readouts change in each patient on treatment. Our scientists interpret those predictions and work with your team to turn them into clear, actionable recommendations. This gives biopharma teams new patient-level data to de-risk business-critical pipeline decisions and make them with greater confidence.